EP1562978A4 - Induction rapide de la formation de la plaque amyloide d'alzheimer par des glycosaminoglycanes sulfates - Google Patents

Induction rapide de la formation de la plaque amyloide d'alzheimer par des glycosaminoglycanes sulfates

Info

Publication number
EP1562978A4
EP1562978A4 EP03778061A EP03778061A EP1562978A4 EP 1562978 A4 EP1562978 A4 EP 1562978A4 EP 03778061 A EP03778061 A EP 03778061A EP 03778061 A EP03778061 A EP 03778061A EP 1562978 A4 EP1562978 A4 EP 1562978A4
Authority
EP
European Patent Office
Prior art keywords
plate formation
rapid induction
alzheimer amyloid
glycosaminoglycans
sulphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03778061A
Other languages
German (de)
English (en)
Other versions
EP1562978A2 (fr
Inventor
Beth P Nguyen
Paula Y Choi
Virginia J Sanders
Gerardo M Castillo
Alan D Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoTech Inc
Original Assignee
ProteoTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProteoTech Inc filed Critical ProteoTech Inc
Publication of EP1562978A2 publication Critical patent/EP1562978A2/fr
Publication of EP1562978A4 publication Critical patent/EP1562978A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP03778061A 2002-11-01 2003-10-31 Induction rapide de la formation de la plaque amyloide d'alzheimer par des glycosaminoglycanes sulfates Withdrawn EP1562978A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42318502P 2002-11-01 2002-11-01
US423185P 2002-11-01
PCT/US2003/034797 WO2004041779A2 (fr) 2002-11-01 2003-10-31 Induction rapide de la formation de la plaque amyloide d'alzheimer par des glycosaminoglycanes sulfates

Publications (2)

Publication Number Publication Date
EP1562978A2 EP1562978A2 (fr) 2005-08-17
EP1562978A4 true EP1562978A4 (fr) 2007-10-10

Family

ID=32312619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03778061A Withdrawn EP1562978A4 (fr) 2002-11-01 2003-10-31 Induction rapide de la formation de la plaque amyloide d'alzheimer par des glycosaminoglycanes sulfates

Country Status (5)

Country Link
EP (1) EP1562978A4 (fr)
JP (1) JP4469281B2 (fr)
AU (1) AU2003286845A1 (fr)
CA (1) CA2504035A1 (fr)
WO (1) WO2004041779A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888937B1 (fr) * 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
CN115335700A (zh) * 2020-03-31 2022-11-11 富士瑞必欧株式会社 血中β淀粉样蛋白的免疫测定方法及用于该方法的试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044669A1 (fr) * 1996-05-23 1997-11-27 Medical Research Council Selection d'agents pour le traitement de la maladie d'alzheimer
WO1999045947A1 (fr) * 1998-03-13 1999-09-16 University Of Washington Formation in vitro de plaques amyloides en forme de croix de malte et ayant une affinite pour le rouge congo, en vue de l'identification de composes therapeutiques anti-plaque pour le traitement de la maladie d'alzheimer et du prion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044669A1 (fr) * 1996-05-23 1997-11-27 Medical Research Council Selection d'agents pour le traitement de la maladie d'alzheimer
WO1999045947A1 (fr) * 1998-03-13 1999-09-16 University Of Washington Formation in vitro de plaques amyloides en forme de croix de malte et ayant une affinite pour le rouge congo, en vue de l'identification de composes therapeutiques anti-plaque pour le traitement de la maladie d'alzheimer et du prion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004041779A2 *

Also Published As

Publication number Publication date
AU2003286845A8 (en) 2004-06-07
AU2003286845A1 (en) 2004-06-07
WO2004041779A3 (fr) 2005-01-13
CA2504035A1 (fr) 2004-05-21
EP1562978A2 (fr) 2005-08-17
JP2006507488A (ja) 2006-03-02
WO2004041779A2 (fr) 2004-05-21
JP4469281B2 (ja) 2010-05-26

Similar Documents

Publication Publication Date Title
EP1374221A4 (fr) Adaptation de synthetiseur de moments d'execution permettant d'ameliorer l'intelligibilite de paroles synthetisees
DE60205588D1 (de) Verdichterlaufrad als Titaniumgusstück
EP1496037A4 (fr) Produit de modification d'acide hyaluronique
EP1489088A4 (fr) Nouveau derive d'alpha-amino-n-(diaminophosphinyl)lactame
AU2003273213A8 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
SG120960A1 (en) Fabricated repair of cast nozzle
EP1424946A4 (fr) Plaques d'osteosynthese
FR2820471B3 (fr) Perfectionnement apporte a la structure d'une vis
EP1568691A4 (fr) Accelerateur de production d'erythropoietine
EE200400107A (et) Protsess kõrgpuhta perindopriili ning sünteesis kasulike vaheühendite valmistamiseks
GB0200206D0 (en) Multi-rate real-time players
PL371426A1 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
FR2853900B1 (fr) Procede de fabrication de l'anhydride isobutyrique
ITPD20020198A1 (it) Piano attrezzato richiudibile per la preparazione di sigarette
ITMI20011361A0 (it) Metodo di purificazione della cicloesanossima
FR2829788B1 (fr) Panneaux modulaires pour la realisation de bassin de piscine
ITMI20041657A1 (it) "testa di filatura"
FR2841883B1 (fr) Butoir pour quai
EP1598076A4 (fr) Inhibiteur de la production d'interleukine 6
DE50207478D1 (de) Pedalarm eines Fahrrades
AU2003286845A8 (en) Amyloid plaque formation by glycosaminoglycans
EP1621210A4 (fr) Activateur de la production d'adiponectine
EP1627051A4 (fr) Regulation de l'expression d'acheron
ITMI20020934A0 (it) Processo per la sintesi di benazepril cloridrato
EE200300438A (et) Pantoteenhappe võimendatud produktsiooni meetod

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070906

17Q First examination report despatched

Effective date: 20080205

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091110